We are live on ! Find out more
DNTH icon

Dianthus Therapeutics
DNTH

70 hedge funds and large institutions have $419M invested in Dianthus Therapeutics in 2019 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 25 increasing their positions, 10 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 10

113% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 8

11% more funds holding

Funds holding: 63 → 70 (+7)

3% more capital invested

Capital invested by funds: $406M → $419M (+$12.6M)

0.09% less ownership

Funds ownership: 4.62% → 4.53% (-0.09%)

50% less funds holding in top 10

Funds holding in top 10: 4 → 2 (-2)

Holders
70
Holders Change
+7
Holders Change %
+11.11%
% of All Funds
1.52%
Holding in Top 10
2
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-50%
% of All Funds
0.04%
New
17
Increased
25
Reduced
10
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
GGHC
Gilder Gagnon Howe & Co
New York
+$36.2M
2
BlackRock
BlackRock
New York
+$7.54M
3
EAM
Eventide Asset Management
Massachusetts
+$6.57M
4
Alkeon Capital Management
Alkeon Capital Management
New York
+$6.18M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$5.87M

Top Sellers

Rank Fund Capital Flow
1
EC
EcoR1 Capital
California
-$21M
2
AG
Artal Group
Luxembourg
-$2.73M
3
Invesco
Invesco
Georgia
-$880K
4
BCM
Bridgeway Capital Management
Texas
-$691K
5
SIM
Spark Investment Management
New York
-$408K
Name Holding Trade Value Shares
Change 		Change in
Stake
Wells Fargo
26
Wells Fargo
California
$443K +$333K +1,345 +253%
BG
27
Bollard Group
Massachusetts
$442K – – –
California State Teachers Retirement System (CalSTRS)
28
California State Teachers Retirement System (CalSTRS)
California
$442K +$118K +479 +34%
Goldman Sachs
29
Goldman Sachs
New York
$358K -$57.9K -234 -13%
AG
30
Artal Group
Luxembourg
$347K -$2.73M -11,030 -88%
RhumbLine Advisers
31
RhumbLine Advisers
Massachusetts
$324K +$103K +415 +43%
New York State Common Retirement Fund
32
New York State Common Retirement Fund
New York
$314K +$256K +1,037 +353%
State of Wisconsin Investment Board
33
State of Wisconsin Investment Board
Wisconsin
$308K +$323K +1,306 New
BFM
34
Boothbay Fund Management
New York
$304K +$319K +1,290 New
OC
35
Oppenheimer & Co
New York
$295K – – –
VEA
36
Virtus ETF Advisers
New York
$274K +$287K +1,161 New
Barclays
37
Barclays
United Kingdom
$242K +$125K +507 +98%
FT
38
Fiduciary Trust
Massachusetts
$221K +$232K +938 New
Bank of America
39
Bank of America
North Carolina
$201K +$27.7K +112 +15%
Manulife (Manufacturers Life Insurance)
40
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$197K +$206K +834 New
ProShare Advisors
41
ProShare Advisors
Maryland
$188K -$989 -4 -0.5%
AIG
42
American International Group
New York
$183K +$49.5K +200 +35%
AllianceBernstein
43
AllianceBernstein
Tennessee
$178K +$187K +756 New
OFS
44
OneAscent Financial Services
Alabama
$166K +$174K +702 New
AWM
45
Aries Wealth Management
Maine
$165K – – –
MIM
46
MetLife Investment Management
New Jersey
$151K +$158K +641 New
TAM
47
Tiverton Asset Management
Delaware
$139K – – –
Citigroup
48
Citigroup
New York
$94K +$31.4K +127 +47%
Deutsche Bank
49
Deutsche Bank
Germany
$87K -$160K -647 -64%
JP Morgan Chase
50
JP Morgan Chase
New York
$79K +$28.4K +115 +53%
1
2
3 4

DNTH Hedge Fund Activity: Q2 2019 in Review

70 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in Dianthus Therapeutics (DNTH) for Q2 2019, worth a combined $419M — up 3.1% from $406M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new DNTH positions and 8 closed out — a net gain of 9 holders — while 25 added to existing stakes and 10 trimmed.

The largest buyer was Gilder Gagnon Howe & Co, adding an estimated $36.2M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $21M sold.

  • 70 institutional investors held Dianthus Therapeutics (DNTH) as of Q2 2019, up from 63 in Q1 2019.
  • Funds reported $419M of Dianthus Therapeutics stock for Q2 2019, up 3.1% quarter-over-quarter.
  • 17 funds opened new Dianthus Therapeutics positions in Q2 2019 and 8 closed out, a net change of +9 holders.
  • The largest Dianthus Therapeutics buyer in Q2 2019 was Gilder Gagnon Howe & Co, an estimated $36.2M added.
  • The largest Dianthus Therapeutics seller in Q2 2019 was EcoR1 Capital, an estimated $21M sold.

Based on aggregated 13F filings for Q2 2019.